COMMUNIQUÉS West-GlobeNewswire

Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
04/11/2025
November 4, 2025 Q3 2025 Group Highlights Comparable order intake growth 8% Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable sales Income from operations was EUR 330 million Adjusted EBITA [...]
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
04/11/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
04/11/2025
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio C3 glomerulopathy (C3G) studies add to body of [...]
Zelluna ASA: Disclosure of large shareholding
04/11/2025
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement [...]
Coloplast A/S - Full-Year Financial Results 2024/25
04/11/2025
2024/25 Full year financial results 1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin 1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and [...]
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
04/11/2025
Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of [...]
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
04/11/2025
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin 1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million. • Organic growth rates by business [...]
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
04/11/2025
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
04/11/2025
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
03/11/2025
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with the FDA to discuss [...]
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
TELA Bio Appoints William Plovanic to Board of Directors
03/11/2025
MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative [...]
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2025
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on [...]
Glucotrack, Inc. Encourages Shareholders to Vote
03/11/2025
The Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. ( [...]
Bitterroot Bio to Present Anti-CD47 Research at American Heart Association Annual Scientific Session 2025
03/11/2025
PALO ALTO, Calif. and NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the Company will present data [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly [...]
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
03/11/2025
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies FRIENDSWOOD, Texas, Nov. 03, 2025 ( [...]
Option Care Health to Participate in Upcoming Investor Conferences
03/11/2025
BANNOCKBURN, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
03/11/2025
NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday [...]

Pages